Results 171 to 180 of about 2,636,574 (342)

Developing a carbon footprint calculation method for product life cycle based on low-carbon design: A case study of the STAGE Bluetooth speaker. [PDF]

PLoS One
Zhang Y, Yao S, Chen Y.
europepmc   +1 more source

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. [PDF]

Front Pharmacol, 2019
van Overbeeke E, Janssens R, Whichello C, Schölin Bywall K, Sharpe J, Nikolenko N, Phillips BS, Guiddi P, Pravettoni G, Vergani L, Marton G, Cleemput I, Simoens S, Kübler J, Juhaeri J, Levitan B, de Bekker-Grob EW, Veldwijk J, Huys I.   +18 more
europepmc   +1 more source

Who Needs Agglomeration? Varying Agglomeration Externalities and the Industry Life Cycle [PDF]

In this paper, the changing roles of agglomeration externalities during different stages of the industry life cycle are investigated. A central argument is that agglomeration externalities vary with mode of competition, innovation intensity, and ...
Frank Neffke, Karl-Johan Lundquist, Lars-Olof Olander, Martin Svensson Henning, Ron Boschma   +4 more
core  

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Innovative Bionics Product Life-Cycle Management Methodology Framework with Built-In Reverse Biomimetics: From Inception to Clinical Validation. [PDF]

Biomimetics (Basel)
Alemzadeh K.
europepmc   +1 more source

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. [PDF]

Patient, 2019
Janssens R, Russo S, van Overbeeke E, Whichello C, Harding S, Kübler J, Juhaeri J, Bywall KS, Comanescu A, Hueber A, Englbrecht M, Nikolenko N, Pravettoni G, Simoens S, Stevens H, Hermann R, Levitan B, Cleemput I, de Bekker-Grob E, Veldwijk J, Huys I.   +20 more
europepmc   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Fluid-structure interaction simulation of mechanical aortic valves: a narrative review exploring its role in total product life cycle. [PDF]

Front Med Technol
Arminio M, Carbonaro D, Morbiducci U, Gallo D, Chiastra C.   +4 more
europepmc   +1 more source

Absorptive capacity, technological innovation, and product life cycle: a system dynamics model. [PDF]

Springerplus, 2016
Zou B, Guo F, Guo J.
europepmc   +1 more source

Forecasting Obsolescence Risk and Product Life Cycle With Machine Learning

IEEE Transactions on Components, Packaging, and Manufacturing Technology, 2016
Connor Jennings, Dazhong Wu, J. Terpenny
semanticscholar   +1 more source